Prolactin, Inflammation, and Parkinson's Severity

The Relationship of Prolactin and Inflammatory Markers With Parkinson's Disease Severity: Clinical and Biochemical Evaluation

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07163156

Acronym

PRIPS

Enrollment

300

Registered

2025-09-09

Start date

2025-08-14

Completion date

2026-06-30

Last updated

2025-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Parkinson Disease, Inflammation, Prolactin, Prolactin Levels

Brief summary

This cross-sectional observational study aims to evaluate the relationship between serum prolactin levels, peripheral inflammatory markers (NLR, PLR, SII, CRP), and disease severity in patients with Parkinson's disease (PD). A total of at least 300 patients diagnosed with idiopathic PD will be included. Disease severity will be assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) and the Modified Hoehn-Yahr staging system. Serum and salivary prolactin levels will be measured using ELISA, while inflammatory markers will be calculated from routine blood tests. The study seeks to clarify whether prolactin and systemic inflammation indicators may serve as non-invasive biomarkers for disease progression and prognosis in PD, with particular emphasis on postmenopausal women.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Age ≥ 18 years * Diagnosis of idiopathic Parkinson's disease confirmed by a neurologist * Both male and postmenopausal female patients * Patients able to provide informed consent * Clinically stable enough to undergo blood and saliva sampling, as well as neurological assessment

Exclusion criteria

* Premenopausal female patients * Patients with secondary or atypical parkinsonism (e.g., drug-induced, vascular, atypical parkinsonian syndromes) * Known endocrine disorders affecting prolactin levels (e.g., prolactinoma, pituitary adenoma, hypothyroidism) * Use of medications known to alter prolactin secretion (e.g., antipsychotics, dopamine antagonists, estrogen therapy) * History of other neurodegenerative diseases (e.g., Alzheimer's, Huntington's) * Presence of active infection, chronic inflammatory disease, or malignancy * Severe renal, hepatic, or cardiac failure * Inability to provide informed consent

Design outcomes

Primary

Measure	Time frame	Description
Systemic inflammatory markers	1 year later	NLR, PLR, SII, CRP
Prolactin Level	1 year later	Serum prolactine levels

Countries

Turkey (Türkiye)

Outcome results